DOCSLIB.ORG

Frances Oldham Kelsey Papers [Finding Aid]. Library of Congress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Frances Oldham Kelsey Papers [Finding Aid]. Library of Congress Frances Oldham Kelsey Papers A Finding Aid to the Collection in the Library of Congress Manuscript Division, Library of Congress Washington, D.C. 2016 Contact information: http://hdl.loc.gov/loc.mss/mss.contact Additional search options available at: http://hdl.loc.gov/loc.mss/eadmss.ms009300 LC Online Catalog record: http://lccn.loc.gov/mm97084006 Prepared by T. Michael Womack with the assistance of Sherralyn McCoy Revised and expanded by Melinda K. Friend with the assistance of Sherralyn McCoy Collection Summary Title: Frances Oldham Kelsey Papers Span Dates: 1890-2016 Bulk Dates: (bulk 1950-2000) ID No.: MSS84006 Creator: Kelsey, Frances Oldham, 1914-2015 Extent: 78,000 items; 253 containers plus 4 oversize; 101.4 linear feet; 103 digital files (3.7MB) Language: Collection material in English Location: Manuscript Division, Library of Congress, Washington, D.C. Summary: Pharmacologist and government official. Correspondence, memoranda, research files, subject file, biographical material, laboratory notebooks and notes, reports and studies, academic material, press releases and clippings, speeches, statements, testimonies, articles and other writings, memorabilia, printed matter, financial records, family and estate papers, reminiscences, card indexes, patient files and records, photographs, microfiche, digital files, and other papers chronicling Kelsey's career as a pharmacologist and instructor at the University of Chicago in Illinois and the University of South Dakota in Vermillion, and as a regulator investigating new drugs at the United States Food and Drug Administration. Selected Search Terms The following terms have been used to index the description of this collection in the Library's online catalog. They are grouped by name of person or organization, by subject or location, and by occupation and listed alphabetically therein. People Geiling, E. M. K. (Eugene Maximilian Karl), 1891- Essentials of pharmacology. 1947. Kelsey, F. E. (Fremont Ellis). Essentials of pharmacology. 1947. Kelsey, F. E. (Fremont Ellis). F.E. Kelsey files. 1939-1968. Kelsey, Frances Oldham, 1914-2015. Kelsey, Frances Oldham, 1914-2015. Essentials of pharmacology. 1947. Swann, John Patrick, 1956- Organizations American Medical Association. National Institutes of Health (U.S.) United States. Food and Drug Administration. United States. Food and Drug Administration. Bioresearch Monitoring Program. United States. Food and Drug Administration. Division of Scientific Investigations. United States. Surgeon-General's Office. University of Chicago--Faculty. University of South Dakota--Faculty. Subjects Civil service--Awards--United States. Drugs--Law and legislation--United States. Drugs--Testing--United States. Fraud in science. Laboratories--Quality control. Medicine--Research. Pharmaceutical policy--United States. Pharmacology. Quacks and quackery. Teratology. Thalidomide. Occupations Pharmacologists. Frances Oldham Kelsey Papers 2 Public officials. Administrative Information Provenance The papers of Frances Oldham Kelsey, pharmacologist and government official, were transferred to the Library of Congress in 1997 by the United States Food and Drug Administration under the instructions of Kelsey. Two later editions were transferred from the United States Food and Drug Administration by John Patrick Swann in 2003. Additions from Kelsey's daughters, Susan Duffield and Christine Kelsey, were received in 2012 and 2016. Processing History The papers of Frances Oldham Kelsey were arranged and described in 1998. The finding aid was revised in 2009. Additional material received between 2003 and 2016 was processed as Part II in 2016. Transfers Items have been transferred from the Manuscript Division to other custodial divisions of the Library. Sound recordings and a DVD have been transferred to the Motion Picture, Broadcasting, and Recorded Sound Division. Some photographs have been transferred to the Prints and Photographs Division. All transfers are identified in these divisions as part of the Frances Oldham Kelsey Papers. Copyright Status Copyright in the unpublished writings of Frances Oldham Kelsey in these papers and in other collections of papers in the custody of the Library of Congress has been dedicated to the public. Access and Restrictions Restrictions apply governing the use, photoduplication, or publication of items in this collection. Consult reference staff in the Manuscript Division for information concerning these restrictions. In addition, many collections are stored off-site and advance notice is needed to retrieve these items for research use. Digital Format Digital files were received as part of the papers of Frances Oldham Kelsey. Reference copies were created from the original digital media. Advanced notice is required for access to digital content; consult reference staff in the Manuscript Division for more information. Preferred Citation Researchers wishing to cite this collection should include the following information: Container number or digital ID number, Frances Oldham Kelsey Papers, Manuscript Division, Library of Congress, Washington, D.C. Biographical Note Date Event 1914, July 24 Born, Cobble Hill, Vancouver Island, British Columbia, Canada 1934 B.Sc., McGill University, Montreal, Quebec, Canada 1935 M.Sc., McGill University, Montreal, Quebec, Canada 1938 Ph.D., Pharmacology, University of Chicago, Chicago, Ill. Frances Oldham Kelsey Papers 3 1938-1950 Instructor, University of Chicago, Chicago, Ill., conducting advanced research in pharmacology; assistant professor, 1946-1950 circa 1941-circa 1946 Civilian, Office of Scientific Research and Development, Malaria Research Program, conducting studies related to the chemotherapy of malaria 1943 Married Fremont Ellis Kelsey (died 1966) 1947 Published with F. E. Kelsey and E. M. K. Geiling Essentials of Pharmacology. Philadelphia: Lippincott; 2nd edition, 1951; 3rd edition, 1955; 4th edition, 1960 1950 M.D., University of Chicago, Chicago, Ill. 1950-1952 Editorial associate, Journal of the American Medical Association, American Medical Association, Chicago, Ill. 1953-1954 Intern, Sacred Heart Hospital, Yankton, S. Dak. 1954-1957 Associate professor of pharmacology, University of South Dakota, Vermillion, S. Dak. Recipient, Lederle Medical Faculty Award 1956 Became a United States citizen 1957-1960 Private medical practice, Vermillion, S. Dak. 1960-1963 Medical officer, Bureau of Medicine, United States Food and Drug Administration 1962 Recipient, President's Award for Distinguished Federal Civilian Service for refusal to approve commercial distribution of thalidomide in the United States 1963-1966 Medical officer, Investigational Drug Branch, Division of New Drugs, Bureau of Medicine, United States Food and Drug Administration 1965 Inducted into National Women's Hall of Fame, New York World's Fair, New York, N.Y. 1966-1967 Director, Division of Oncology and Radiopharmaceutical Drug Products, Office of New Drugs, Bureau of Medicine, United States Food and Drug Administration 1967-1968 Assistant to the director for Scientific Investigations, Bureau of Medicine, United States Food and Drug Administration 1968-1971 Director, Division of Scientific Investigations, Office of Medical Support, Bureau of Medicine, United States Food and Drug Administration 1971-1977 Director, Scientific Investigations Staff, Office of Scientific Evaluation, Bureau of Drugs, United States Food and Drug Administration 1977-1982 Director, Division of Scientific Investigations, Office of Scientific Evaluation, Bureau of Drugs, United States Food and Drug Administration Frances Oldham Kelsey Papers 4 1982-1987 Director, Division of Scientific Investigations, Office of Compliance, Center for Drugs and Biologics, United States Food and Drug Administration 1987-1995 Director, Division of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration 1995-200? Deputy for Scientific and Medical Affairs, United States Food and Drug Administration 2000 Inducted into National Women's Hall of Fame, Seneca Falls, N.Y. 2005 Retired from United States Food and Drug Administration 2010 Recipient, first Drug Safety Excellence Award, United States Food and Drug Administration; award renamed The Dr. Frances O. Kelsey Drug Safety Excellence Award 2014 Moved to London, Ontario, Canada 2015 Named to the Order of Canada 2015, Aug. 7 Died, London, Ontario, Canada Scope and Content Note Introduction The papers of Frances Oldham Kelsey (1914-2015) span the years 1890-2016, with the bulk of the items concentrated between 1950 and 2000. The collection consists of two parts. Part I covers Kelsey's career as a pharmacologist and government official at the United States Food and Drug Administration (FDA), primarily from 1960 to 1990. Part II comprises the bulk of the collection and documents Kelsey career in pharmacolgy before and during her years at the FDA. Further descriptions of each part follow. Excisions of information from some of the documents in the collection were carried out by the FDA. Part I Part I of the papers spans the years 1913-1998, with the bulk of the items concentrated in the period between 1960 and 1990. Part I includes Kelsey's files created during her work as a pharmacologist and government official at the FDA and consists of three series: Office File , Speeches and Writings File , and Research File . Included in the papers are biographical material, correspondence, memoranda, speeches, editorials, background information and chapter drafts
Load more

Recommended publications
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Virtual Mentor American Medical Association Journal of Ethics July 2001, Volume 3, Number 7: 252-254
    Virtual Mentor American Medical Association Journal of Ethics July 2001, Volume 3, Number 7: 252-254. VIEWPOINT Protecting the Public: Profile of Dr. Frances Oldham Kelsey Karen Geraghty That Dr. Frances Oldham Kelsey saved countless lives and prevented numerous physical deformities of infants and children is a remarkable accomplishment in any career. More remarkable still is the fact that she accomplished this feat not through the discovery of a cure, the development of an innovative surgical procedure, or the invention of a life-saving device. Rather, it was Dr. Kelsey's professional behavior—her unwillingness to compromise the priorities of patient health and safety—that single-handedly averted an appalling tragedy nearly thrust upon an unsuspecting American public. In September 1960, Dr. Kelsey was a newly appointed member of the Food and Drug Administration (FDA). Her very first assignment was to review the application for the drug Kevadon. Synthesized in 1954 and introduced to the market on October 1, 1957 in West Germany, the drug—known there by the name Thalidomide—was hailed as a wonder cure for insomnia. Non-addictive and non- toxic, Thalidomide induced sleep and was prescribed as a sedative that promised no side effects. As its popularity grew, it soon became the drug of choice prescribed to pregnant women combating symptoms associated with morning sickness. By 1960, Thalidomide was popularly prescribed throughout the world, including Europe and Canada. The application by the Richardson-Merrell pharmaceutical company of Cincinnati to introduce Thalidomide under the brand name Kevadon to the US market reached the desk of Dr. Kelsey less than one month after her appointment to the FDA.
    [Show full text]
  • Silent Spring at 50: Reflections on an Environmental Classic
    SILENT SPRING AT 50: REFLECTIONS ON AN ENVIRONMENTAL CLASSIC PERC POLICY SERIES • NO. 51 • 2012 BY ROGER E. MEINERS & ANDREW P. MOrrISS Editor Laura E. Huggins PERC 2048 Analysis Drive Suite A Bozeman‚ Montana 59718 Phone: 406–587–9591 Fax: 406–586–7555 www.perc.org [email protected] RECENT EssaYS PERC POLICY SERIES PS-50 Colony Collapse Disorder: The Market Response to Bee Disease Randal R. Rucker and Walter N. Thurman PS-49 Fencing Fisheries in Namibia and Beyond: Lessons from the Developing World Laura E. Huggins PS-48 Designing Payments for Ecosystem Services James Salzman PS-47 Recycling Myths Revisited Daniel K. Benjamin PS-46 Environmental Water Markets: Restoring Streams through Trade Brandon Scarborough PS-45 Two Forests under the Big Sky: Tribal v. Federal Management Alison Berry PS-44 7 Myths About Green Jobs Andrew P. Morriss‚ William T. Bogart‚ Andrew Dorchak‚ and Roger E. Meiners PS-43 Creating Marine Assets: Property Rights in Ocean Fisheries Robert T. Deacon PS-42 Environmental Justice: Opportunities through Markets H. Spencer Banzhaf PS-41 Do Profits Promote Pollution? The Myth of the Environmental Race to the Bottom Robert K. Fleck and Andrew Hanssen ISSN 1094–655 Copyright © 2012 by PERC. All papers are available at www.perc.org. Distribution beyond personal use requires permission from PERC. TABLE OF CONTENTS 2 HISTORICAL BACKGROUND 6 The PerFecT CheMICAL STORM 9 BIRD POPULATIONS AND DDT 14 CANcer FROM PESTICIDES 16 SILENce ON TOBACCO 17 WHAT ABOUT The CHILDreN? 17 ENVIRONMENTAL CONTAMINANTS & CANcer 20 OVerLOOKED BeNEFITS OF PESTICIDES 23 The OTher ROAD 24 Are CheMICAL PESTICIDES A NeceSSARY EVIL? 25 CONCLUSION 25 REFERENCES 28 cASE CITED TO The reADer By dramatically revealing the potential dangers synthetic chemicals posed to the environment and human health‚ Rachel Carson’s Silent Spring (1962a) served as a catalyst for the modern environmental movement.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • President's Message
    Summer/Fall Issue 2014 SOT News President’s Message With summer quickly coming to an end and a new school year almost upon us, it draws my attention to one of the most important services that the Society of Toxicology (SOT) provides to its membership, Continuing Education (CE). The Society provides a variety of mechanisms for members to continue their professional growth and development. I would like to bring to your attention two specific opportunities on the horizon. The first comes from a recent partnership between the US Food and Drug Administration’s (FDA) Center for Food Safety and Applied Nutrition and SOT. Specifically, the US FDA and SOT will collaborate on providing four half- day sessions over the next year on current topics of mutual interest. This series of sessions, termed the “SOT FDA Colloquia on Emerging Toxicological Science Challenges in Food and Ingredient Safety,” will be open for public attendance as well as available for viewing via webcast. The symposia also will be recorded with links available through the SOT website to President view at your convenience. Norbert E. Kaminski The first of four sessions will focus on partially hydrogenated oils (PHO), often referred to as “trans fats.” This first colloquium, which is tentatively scheduled for October 2014, will cover a variety of topics including, but not limited to, the US FDA recent actions on PHO, the chemistry and biochemistry of PHO and related lipids, the clinical effects of PHO including health hazards and benefits, and will conclude with a moderated roundtable discussion with speakers and invited panelists.
    [Show full text]
  • THE REAL DEAL Meet Dean Jane Aiken Wake Forest Jurist | 1 WAKE FOREST JURIST
    THE MAGAZINE OF WAKE FOREST LAW 2020 THE REAL DEAL Meet Dean Jane Aiken Wake Forest Jurist | 1 WAKE FOREST JURIST 2020 Volume 50 ON THE COVER Jane Aiken, Dean of Wake Forest University School of Law EXECUTIVE DIRECTOR PHOTOGRAPHY Wake Forest Jurist is published by Jorge Reyna Allen Aycock Wake Forest University School of Ken Bennett Law. All rights reserved. The views EDITORS Bladen Journal expressed herein do not necessarily Stephanie Skordas Shawn Miller (New York Times) reflect those of Wake Forest Univer- Kaitlyn Ruhf (BA ’13, MA ’20) Robert Ross sity School of Law. Kaitlyn Ruhf (BA ’13, MA ’20) ASSOCIATE EDITOR/ART United States Senate Photographic Services SEND CLASS NOTES TO: DIRECTOR [email protected] Holly Swenson WEBSITE or Trevor Hughes Jurist Notes CONTRIBUTORS Matt Nelkin P.O. Box 7205 Michael Breedlove Winston-Salem, NC 27109 or The Jurist Website 2 | law.wfu.edu jurist.law.wfu.edu WAKE FOREST JURIST 4 THE REAL DEAL EFFECTIVE PANDEMIC A FOND 16 IMMEDIATELY 24 PRO-TEMPORE 38 FAREWELL EVENTS 48 FACULTY HIGHLIGHTS 50 CLASS NOTES 54 Wake Forest Jurist | 1 2 | law.wfu.edu A MESSAGE FROM THE DEAN DRAWING ON OUR STRENGTHS, OUR RESILIENCE, AND OUR HOPE When the dust settles, we will likely be looking back on 2020 as a generation-defining year for our communities, our country, and our world. But perhaps it need not be because of the limitations that the virus suddenly imposed upon us, but because of the resilience, ingenuity, speed, and commitment with which we are adapting and rising to meet the momentous challenge being thrust upon us.
    [Show full text]
  • Autobiographical Reflections
    AUTOBIOGRAPHICAL REFLECTIONS FRANCES OLDHAM KELSEY, Ph. D., M. D. Early Life and Education 3 Research, Professional Development, and Family in Chicago 13 Medical Teaching, Research, and Practice in South Dakota 33 Coming to FDA and an Introduction to the Drug Approval Process 43 Thalidomide 49 Post-Drug Amendments Reorganizations of New and Investigational Drugs in the Bureau of Medicine 79 Creation and Work of the Division of Scientific Investigations 81 2 1 AUTOBIOGRAPHICAL REFLECTIONS Frances O. Kelsey, Ph. D., M. D. In thinking about my life, I recall a letter I received in 1987 from an eighth grader in Vermillion, South Dakota, and I remember this for two reasons: first, we had lived in Vermillion, and my daughters went to the Jolley School where this girl was an eighth grader. But, second, because she asked me some questions that I did not feel I answered very well at the time she asked them, and I thought I might weave the answers into my reflections. The girl had to give a speech at her school on a woman who had a career in spite of obstacles. She had gotten a little background information on me from the library and seemed to have done a good job. She asked me for a few more facts, but what drew me up short was when she said: "But, most of all, perhaps you could describe how hard it was to be a woman studying science and medicine when most of your classmates were men. Perhaps you could also tell me how frustrating it must have been to find work when most people thought a woman should only be a housewife." So I thought in reflecting on my life and my 1 Editorial note: This was drawn from the following: oral history interviews conducted in 1974, 1991, and 1992; presentation, Founder’s Day, St.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet Al
    US009248195B2 (12) United States Patent (10) Patent No.: US 9.248,195 B2 Rariyet al. (45) Date of Patent: *Feb. 2, 2016 (54) ABUSE-DETERRENT PHARMACEUTICAL (52) U.S. Cl. COMPOSITIONS OF OPODS AND OTHER CPC ............... A61K 47/46 (2013.01); A61 K9/1617 DRUGS (2013.01); A61 K9/5026 (2013.01); A61 K 31/485 (2013.01); A61K 45/06 (2013.01); (71) Applicant: COLLEGIUM PHARMACEUTICAL, A61K47/12 (2013.01) INC., Canton, MA (US) (58) Field of Classification Search (72) Inventors: Roman V. Rariy, Allston, MA (US); CPC ......... A61K 9/141; A61 K9/148: A61 K9/20: Alison B. Fleming, North Attleboro, MA A61 K9/48: A61 K9/145; A61 K9/16: A61 K (US); Jane Hirsh, Wellesley, MA (US); 9/1617; A61 K9/50: A61 K9/2013: A61 K Alexander M. Klibanov, Boston, MA 9/2077; A61K31/135; A61K31/485 (US) See application file for complete search history. (73) Assignee: Collegium Pharmaceutical, Inc., (56) References Cited Canton, MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 2,404,319 A 7, 1946 Shelton U.S.C. 154(b) by 114 days. 3,015,128 A 1/1962 Somerville, Jr. 3,336,200 A 8, 1967 Krause et al. This patent is Subject to a terminal dis 3,773.955 A 11/1973 Pachter et al. claimer. 3,966,940 A 6, 1976 Pachter et al. 3,980,766 A 9, 1976 Shaw et al. (21) Appl. No.: 14/054,513 4,070,494 A 1/1978 Hoffmeister et al.
    [Show full text]
  • Issue Affirmative Approvals of Many Classes of Products Before Primary Generalized Tonic-Clonic Seizures in Children and Adults They Can Be Marketed
    6 | GLOBAL CALENDAR DECEMBER 2015 9–10 Sterile Product JANUARY 2016 Manufacturing Facilities: ® 1–2 ISPE DACH Affiliate GAMP 5 Applying the ISPE Baseline 12 Delaware Valley Chapter January Conference Guide and FDA Guidance Program Mannheim, Germany Principles to Design and Philadelphia, Pennsylvania, US Operation (T12) Training 3 ISPE UK Affiliate Plant Tour Tampa, Florida, US 21 ISPE DACH Affiliate Stakeholder and Presentation Management Tredegar, Gwent, UK Facility Project Management Frankfurt, Germany in the Regulated CASA Education Event & Charity Pharmaceutical Industry* 21–22 ISPE DACH Affiliate Stakeholder Event (T26) Training Management: Wie Geht Das? Raleigh–Durham, North Carolina, Tampa, Florida, US Neu-Isenberg, Germany US Applying Quality Risk 23 Delaware Valley Chapter Future San Francisco/Bay Area Chapter Management (QRM) (T42) Cities Competition Evening Meeting Training Philadelphia Location TBD Tampa, Florida, US 25–27 Basic Principles of 4 Delaware Valley Chapter 10 ISPE Italy Affiliate Xmas Computerized Systems Volunteer Day Night & Single Use Technology Compliance Using GAMP® 5, Milan, Italy Including Revised Annex 11 Rocky Mountain Chapter and Part 11 Update Holiday Event Midwest Chapter End of Year (T45) Training Boulder, Colorado, US Dinner Tampa, Florida, US 7–8 Australasia Affiliate Best Boston Area Chapter Industrial 28–29 A GAMP® Approach to Practices in Aseptic Processes Wireless Network Data Integrity, Electronic Melbourne, Victoria, Australia Andover, Massachusetts, US Records and Signatures, and Operation
    [Show full text]
  • Naturopathic Physicians Regulation
    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
    [Show full text]